Journal of Stem Cell Research & Therapy

Applications and Significance of Pluripotent Stem

Cristina Molina^* Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
^*Correspondence: Cristina Molina, Department of Biological Sciences, Middle East Technical University, Ankara, Turkey, Email:

Received: 03-Mar-2023, Manuscript No. JSCRT-23-20733; Editor assigned: 06-Mar-2023, Pre QC No. JSCRT-23-20733(PQ); Reviewed: 21-Mar-2023, QC No. JSCRT-23-20733; Revised: 28-Mar-2023, Manuscript No. JSCRT-23-20733(R); Published: 07-Apr-2023, DOI: 10.35248/2157-7633.23.13.591

Description

Pluripotent stem cells are a type of stem cell that has the ability to differentiate into any cell type within the body. They are capable of self-renewal, meaning that they can divide and produce more stem cells, and can also differentiate into a variety of specialized cell types, including nerve cells, muscle cells, and blood cells. This unique ability has made pluripotent stem cells an area of intense research interest, with potential applications in regenerative medicine, disease modeling, and drug development. There are two main types of pluripotent stem cells: Embryonic Stem Cells (ESCs) and Induced Pluripotent Stem Cells (iPSCs). ESCs are derived from the inner cell mass of a developing embryo and are capable of generating all of the cell types that make up the adult body. On the other hand, are generated by reprogramming adult cells, such as skin cells, to a pluripotent state. This reprogramming involves the introduction of specific transcription factors, which activate the same genes that are active in ESCs, allowing the cells to become pluripotent.

Pluripotent stem cells have many potential applications in regenerative medicine. One of the most promising areas of research involves the use of pluripotent stem cells to replace damaged or diseased cells or tissues. For example, pluripotent stem cells could be used to generate new nerve cells to treat conditions such as Parkinson's disease or spinal cord injuries, or to create new blood cells to treat disorders such as leukemia. In addition to their potential use in regenerative medicine, pluripotent stem cells are also being used in disease modeling and drug development. By generating pluripotent stem cells from patients with genetic disorders, researchers can study the underlying mechanisms of these diseases in a controlled environment. This can lead to the development of new treatments and therapies for these conditions. Pluripotent stem cells can also be used to test the safety and efficacy of new drugs, potentially reducing the need for animal testing. Despite their potential applications, the use of pluripotent stem cells is not without controversy. ESCs, in particular, have been the subject of ethical debates due to the fact that they are derived from embryos. This has led to restrictions on the use of federal funding for ESC research in some countries, including the USA. However, the development of iPSCs has largely circumvented these ethical concerns, as they can be generated from adult cells without the need for embryos [1-7].

Another challenge associated with the use of pluripotent stem cells is the risk of teratoma formation. Teratomas are tumors that contain cells from all three germ layers (ectoderm, mesoderm, and endoderm), which can develop when pluripotent stem cells are transplanted into an animal or human. While the risk of teratoma formation can be minimized through careful cell selection and differentiation protocols, it remains a potential concern in the clinical use of pluripotent stem cells. In addition to the challenges associated with the use of pluripotent stem cells, there have also been many advances in the field that have improved our understanding of their biology and potential applications. For example, researchers have developed new methods for generating iPSCs that are more efficient and reliable than previous techniques. They have also made progress in understanding the molecular mechanisms that control pluripotency and differentiation, which could lead to the development of more effective differentiation protocols. One of the most exciting recent advances in the field of pluripotent stem cells has been the development of "naive" pluripotent stem cells. Naive pluripotent stem cells are cells that resemble the cells of the inner cell mass of the early embryo, and are thought to have greater potential for differentiation than traditional pluripotent stem cells [8-10].

References

1. Campuzano V, Montermini L, Molto MD, Pianese L, Cossée M, Cavalcanti F, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-1427.

   [Crossref] [Google Scholar] [PubMed]

2. Cao F, Wagner RA, Wilson KD, Xie X, Fu JD, Drukker M, et al. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS one. 2008;3(10):e3474.

   [Crossref] [Google Scholar] [PubMed]

3. Carvajal-Vergara X, Sevilla A, D’Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465(7299):808-812.

   [Crossref] [Google Scholar] [PubMed]

4. Cheng KW, Agarwal R, Mitra S, Mills GB. Rab25 small GTPase mediates secretion of tumor necrosis factor receptor superfamily member 11b (osteoprotegerin) protecting cancer cells from effects of TRAIL. J Genet Syndr Gene Ther. 2013;4:1000153.

   [Crossref] [Google Scholar] [PubMed]

5. Chestkov IV, Vasilieva EA, Illarioshkin SN, Lagarkova MA, Kiselev SL. Patient-specific induced pluripotent stem cells for SOD1-associated amyotrophic lateral sclerosis pathogenesis studies. Acta Naturae.2014;6(1):54-60.

   [Google Scholar] [PubMed]

6. Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, et.al Efficient drug screening and gene correction for treating liver disease using patient‐specific stem cells. Hepatology.2013;57(6):2458-2468.

   [Crossref] [Google Scholar] [PubMed]

7. Chun Y, Byun K. Lee В. Induced pluripotent stem cells and personalized medicine: current progress and future perspectives. Anat. Cell Biol. 2011;44:245-255.

   [Crossref] [Google Scholar] [PubMed]

8. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):9-18.

   [Crossref] [Google Scholar] [PubMed]

9. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H. Parkinson’s disease induced pluripotent stem cells with triplication of the αsynuclein locus. Nat Commun. 2011;2:440.

   [Crossref] [Google Scholar] [PubMed]

10. Mary A, Dayan J, Leone G, Postel C, Fraisse F, Malle C, et al. Resilience after trauma: The role of memory suppression. Science. 2020;367(6479):8477.

    [Crossref] [Google Scholar] [PubMed]